April 19, 2018 / 12:08 PM / a month ago

BRIEF-Argos Therapeutics Reports Results Of Interim Analysis Of The Adapt Trial And Announces Review Of Strategic Alternatives

April 19 (Reuters) - Argos Therapeutics Inc:

* ARGOS THERAPEUTICS REPORTS RESULTS OF INTERIM ANALYSIS OF THE ADAPT TRIAL AND ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES

* ARGOS THERAPEUTICS INC - COMPANY TO TERMINATE ADAPT STUDY

* ARGOS THERAPEUTICS INC - COMPANY HAS RETAINED STIFEL TO PROVIDE ADVICE ON POSSIBLE STRATEGIC ALTERNATIVES

* ARGOS THERAPEUTICS INC - TRADING IN COMMON STOCK TO BE TRANSFERRED FROM NASDAQ TO OTCQB VENTURE MARKET

* ARGOS THERAPEUTICS - STRATEGIC ALTERNATIVES MAY INCLUDE A POTENTIAL MERGER OR SALE OF CO

* ARGOS - ESTIMATED MEDIAN OVERALL SURVIVAL FOR COMBO ARM WAS 28.2 MONTHS VERSUS 31.2 MONTHS FOR CONTROL ARM IN MOST RECENT ANALYSIS OF ADAPT TRIAL DATA

* ARGOS - TWO OTHER CO-PRIMARY ENDPOINTS IN ADAPT TRIAL ALSO DID NOT DEMONSTRATE A FAVORABLE RESULT

* ARGOS - FOURTH ENDPOINT, FIVE-YEAR SURVIVAL, WAS NOT EVALUATED IN ADAPT TRIAL AS THERE WAS INSUFFICIENT DATA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below